Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2016-07-04 Transaction in Own Shar…
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Transaction in Own Shares Classification · 1% confidence The document is a press release regarding the 'Bilan semestriel du contrat de liquidité' (semi-annual report of the liquidity contract) for GeNeuro. It details the number of shares and cash balance held in the liquidity account as of June 30, 2016. This type of disclosure, which reports on the company's share repurchase/liquidity program activities, falls under the 'Transaction in Own Shares' category.
2016-07-04 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release announcing that GeNeuro has been included in the CAC Mid & Small, CAC Small, and CAC All-Tradable indices on Euronext. This is a corporate announcement regarding market index inclusion, which does not fit into specific financial reporting categories like 10-K, IR, or ER. As it is a general regulatory/corporate announcement, it falls under the RNS (Regulatory Filings) category.
2016-06-20 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release announcing the inclusion of GeNeuro in Euronext stock indexes. It does not report financial results, dividends, or governance changes, nor is it a formal regulatory filing required by a specific form. As it is a general corporate announcement regarding market visibility and index inclusion, it falls under the 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement.
2016-06-20 English
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 1% confidence The document is a monthly disclosure of total voting rights and share capital, which is a standard regulatory requirement in France (AMF General Regulations). It provides the number of shares and voting rights as of a specific date. This type of filing is a standard regulatory disclosure regarding share capital structure and voting rights, which falls under the 'Regulatory Filings' category as it does not represent a specific shareholder vote result (DVA), a major shareholding notification (MRQ), or a share issuance (SHA).
2016-06-03 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure required by Article 223-16 of the AMF General Regulation, which mandates that listed companies provide monthly updates on the total number of shares and voting rights. This type of filing is a standard regulatory requirement for transparency regarding capital structure and does not fit into specific categories like 'Share Issue' (which would imply a change event) or 'Annual Report'. It is a routine regulatory filing.
2016-06-03 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Regulatory Filings Classification · 1% confidence The document is a press release issued by GeNeuro announcing the commencement of a Phase 2b clinical trial for its multiple sclerosis drug candidate, GNbAC1. It details the study design, patient enrollment, and the partnership with Servier. As this is a general regulatory announcement regarding company operations and clinical progress that does not fit into specific financial reporting categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2016-05-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.